Supplemental Financial Information

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Supplemental Financial Information

Supplemental Financial Information

Note 2

Supplemental Financial Information

Inventories

(in millions)	March 31, 2013	December 31, 2012
Finished goods	$613	$547
Work-in-process	262	286
Raw materials	162	258
Inventories, net	$1,037	$1,091

Property and Equipment, Net

(in millions)	March 31, 2013		December 31, 2012
Property and equipment, gross	6,545		6,542
Less accumulated depreciation	(4,345	)	(4,295	)
Property and equipment, net	$2,200		$2,247

Depreciation expense for the three months ended March 31, 2013 and 2012 was $92 million and $140 million, respectively.

Interest Expense (Income), Net

	Three months ended March 31,
(in millions)	2013		2012
Interest expense	$72		$—
Interest income	(6	)	(1	)
Interest expense (income), net	$66		$(1	)

Note 3  Supplemental Financial Information

Interest Expense, net

years ended December 31 (in millions)	2012			2011			2010
Interest and dividend income	$	(20	)	$	(20	)	$	(28	)
Interest expense		104			—			—
Interest expense, net	$	84		$	(20	)	$	(28	)

Other (Income) Expense

Other (income) expense, net, for 2012 included income of $21 million from the resolution of a contractual agreement and a loss of $52 million for the impairment of an equity security. Other (income) expense, net, included losses of $29 million in 2012 and $56 million in 2011 of fair value adjustments and accretion in the contingent consideration related to the acquisition of Solvay SA's U.S. pharmaceuticals business (Solvay). Other (income) expense, net, for 2012, 2011 and 2010 also included ongoing contractual payments from Takeda associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture in 2008.

Accounts Payable and Accrued Liabilities

as of December 31 (in millions)	2012		2011
Sales rebates	$	1,616	$	1,537
Accounts payable		556		417
Salaries, wages and commissions		523		435
Royalty license arrangements		398		417
Government investigation		—		1,509
Acquired IPR&D		—		400
Other		1,718		1,166
Accounts payable and accrued liabilities	$	4,811	$	5,881

Long-Term Liabilities

as of December 31 (in millions)	2012		2011
Deferred income taxes	$	360	$	646
Pension and other post-employment benefits		979		397
Other		900		617
Long-term liabilities	$	2,239	$	1,660

Accumulated Other Comprehensive Income (Loss)

The net-of-tax components of AOCI, a component of parent company equity, were as follows.

as of December 31 (in millions) (brackets denote loss)	2012			2011
Cumulative foreign currency translation gain adjustments	$	181		$	8
Pension and other post-employment benefits		(511	)		(65	)
Cumulative unrealized gains on marketable equity securities		1			26
Cumulative losses/gains on derivative instruments designated as cash flow hedges		(21	)		6
Accumulated other comprehensive loss	$	(350	)	$	(25	)